UK Markets close in 7 hrs 9 mins
  • FTSE 100

    7,083.37
    +102.39 (+1.47%)
     
  • FTSE 250

    23,784.54
    +173.15 (+0.73%)
     
  • AIM

    1,268.13
    +8.00 (+0.63%)
     
  • GBP/EUR

    1.1642
    -0.0005 (-0.04%)
     
  • GBP/USD

    1.3619
    -0.0045 (-0.3282%)
     
  • BTC-GBP

    32,013.03
    +1,722.19 (+5.69%)
     
  • CMC Crypto 200

    1,089.55
    +49.07 (+4.72%)
     
  • S&P 500

    4,395.64
    +41.45 (+0.95%)
     
  • DOW

    34,258.32
    +338.48 (+1.00%)
     
  • GOLD FUTURES

    1,768.40
    -9.80 (-0.55%)
     
  • NIKKEI 225

    29,639.40
    -200.31 (-0.67%)
     
  • HANG SENG

    24,221.54
    +122.40 (+0.51%)
     
  • DAX

    15,506.74
    +158.21 (+1.03%)
     
  • CAC 40

    6,637.00
    +84.27 (+1.29%)
     

Orion will remain as the owner of pharmaceutical manufacturing plant in Kuopio, Finland

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

ORION CORPORATION PRESS RELEASE 17 AUGUST 2021 at 8.00. a.m. EEST

Orion will remain as the owner of pharmaceutical manufacturing plant in Kuopio, Finland

Orion Corporation announced on 25 May 2021 that it had evaluated strategic alternatives of its Global Operations and had decided to investigate the possible sale of its pharmaceutical manufacturing plant in Kuopio or other transaction that would result in the transfer of the plant outside the Orion Group.

The outcome of the investigation was that Orion will remain as the owner of the plant in question.

Orion’s manufacturing plant in Kuopio specialises in liquids and self-care products. Among the most widely known of these are nasal sprays, cough medicines, and ear drops.

The Kuopio plant has around 50 employees working in Global Operations. Orion’s Global Operations and Quality Management consist of around 1,800 employees in total.


Contact person:

Terhi Ormio
Vice President, Communications, Orion Corporation
Tel. +358 50 966 4646
terhi.ormio@orion.fi


Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo
Homepage: www.orion.fi/en

Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion’s pharmaceutical R&D are neurological disorders, oncology and respiratory diseases for which Orion develops inhaled pulmonary medication. Orion’s net sales in 2020 amounted to EUR 1,078 million, and the company had about 3,300 employees at the end of the year. Orion’s A and B shares are listed on Nasdaq Helsinki.


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting